New properties and roles for eosinophils in disease: discussion paper' Christopher J F Spry FRCP FRCPath Department ofImmunology, Royal Postgraduate Medical School, London W12 OHS During the last ten years there have been a number of fundamental changes in our views about the properties of eosinophils, and their capacity to take part in inflammatory reactions. In addition, a number of diseases with a marked eosinophilia have been defined, and this has led to fresh concepts about the properties of eosinophils and their roles in human disease.
Regulation of eosinophil production Sixteen years ago it became clear that T lymphocytes, or factors secreted by T lymphocytes, were involved in the regulation of eosinophil production, at least in rodents (Basten & Beeson 1970 , Beeson & Bass 1977 . Although work continued in this area, there was no clear definition of the nature of these factors, but more recently there have been some significant developments. Firstly it has been shown that genetic factors are involved in regulating eosinophil production in mice (Vadas 1982) . Secondly, it was recognized that a number of molecules, which may be closely related, have marked eosinophil growth-promoting actions on cultured human bone marrow cells leading to the development of eosinophil colonies in vitro (Vadas 1983 ). These factors have been derived from a number of tissues, and include placental cells, tumour cells and cloned T lymphocytes (Warren & Sanderson 1985) . Factors have been isolated and defined most extensively from placental cells, and from a carcinoma of the lung which was associated with a marked hypereosinophilia (Slungaard et al. 1983 ). Attempts to demonstrate a serum eosinopoietic factor (able to induce eosinophil colony development in vitro) have only been successful in the patient with carcinoma of the lung. More sensitive assays for human eosinopoietic factor(s) are clearly needed, and it will be important to see whether these factors are involved in the development of eosinophilia in parasitic and other diseases. Thirdly, injections of cyclophosphamide together with parasitic or other stimuli have been used to induce a marked eosinophilia in rodents (Vadas 1981 , Sugane & Oshima 1985 . It has also been found that injections of purified recombinant interleukin 2 (IL2) into patients with malignant diseases can give rise to a marked eosinophilia (Lotze et al. 1985) . However, it is not yet known whether this is in effect of IL2 itself on eosinophil production, or a secondary effect of some contaminant, or even a hypersensitivity reaction.
Eosinophil constituents
Biochemical and molecular biological studies on eosinophil constituents have moved ahead in the last few years, thanks to the considerable effort of several groups in Sweden and the USA. The main findings have been that eosinophil granules contain at least four basic proteins which are toxic to some parasites and mammalian cells (Gleich & Loegering 1984) . The mechanisms of parasite and cell killing are complex, but may be similar to the effects of other basic proteins, including the late complement components or mellitin. A direct inhibitory effect on respiration has been demonstrated in isolated heart cells (Tai et al. 1982) . Eosinophil toxic proteins have been difficult to isolate and study because of their basic properties, but a number of immunoassays have now been developed. These have shown striking changes in serum levels in parasitic and allergic diseases. Unfortunately serum levels have not correlated with any particular disease process, and they have not yet reached the stage where they would be useful in differential diagnosis, or treatment (Hallgren et al. 1979 ). This may be related to the binding properties of these proteins for cell membranes and other tissues, leaving only residual protein to be assayed in the serum.
Although the amino acid composition of some of these proteins is known, and from which it has been shown that the major basic protein is dissimilar from the eosinophil cationic protein (ECP), sequence results have not yet been reported. This is partly because in vitro studies with eosinophil RNA have been difficult to carry out, since the basic nature of the proteins interferes with the RNA extraction process. Biosynthetic studies of eosinophil basic proteins have only just begun, and these may show some important structural post-translational changes in these proteins, both in the storage form and prior to secretion (Olsson et al. 1985) . There is also a hint that ECP and the eosinophil neurotoxin are biochemically related, and may belong to a family of proteins. Monoclonal antibodies have been raised which distinguish the storage from the secreted forms of the cationic protein (Tai et al. 1984b) , indicating the complexity of the structural changes that occur when they are synthesized and stored, and then solubilized and secreted. The secreted products are presumably the key components which take part in inflammatory reactions. We still know relatively little about the properties of each individual protein, and there may be some surprises in the future, once each of these constituents has been tested in a highly pure form in a wide range of assay systems. These should include studies on brain cells, vascular endothelium, platelets and fibroblasts, as neurological disease (Moore et al. 1985) , thromboembolic disease , and fibrosis are all features of the hypereosinophilic syndrome (Spry 1982) , for which there is, as yet, no explanation.
Eosinophil activation
Studies on the metabolism of eosinophils are also at an early stage, but these have shown already that eosinophils go through a late differentiation stage, after they have entered the blood, when they acquire an increased capacity to metabolize oxygen and glucose (Bass et al. 1982) . Because this later stage is associated with an increased capacity of eosinophils to kill parasites in vitro, it has been termed 'activation'. Activation (in this strict sense) is comparable to macrophage activation, as in both cell types it is now known to be induced by lymphokines (Dessein et al. 1982 , Veith et al. 1984 . The eosinophil activating factor (EAF), which is distinct from the macrophage activating factor, has been isolated recently (Thorne et al. 1985) and large amounts can now be made using cell lines (Silberstein et al. 1985) . Activation appears to be a final step in the development of the full biological properties of eosinophils. Earlier work, on blood eosinophils from normal individuals, may have underestimated their capacity to take part in inflammatory reactions because of this. The ways in which activating factors induce these altered properties of eosinophils is not yet known, but may involve alterations in the stored granule proteins themselves. In vivo, activation is usually associated with an alteration in eosinophil density (Prin et al. 1983) .
Two further features of stimulated eosinophils have come to light in the last few years. The first in their capacity to make large amounts of the SRS-A leukotrienes, particularly LTC4 (Henderson et al. 1984 , Shaw et al. 1985 . This is not a feature of neutrophils, and it emphasizes that some of the roles of eosinophils are linked to their presence in acute allergic reactions. Much interest is directed at finding out whether eosinophils produce sufficient leukotrienes to affect the lungs in asthma, and the gut and skin in other disorders. There is special interest in the possible role of eosinophils in aspirin-sensitive respiratory diseases. One interesting suggestion is that stimulated eosinophils, which are present in the lung in patients with asthma, might produce toxic substances which damage the epithelium of the lung (Gleich et al. 1985 , Sun et al. 1985 , leading to the loss of the regulatory effects of epithelium on underlying smooth muscle.
A second property of activated eosinophils is that they are able to make large amounts of platelet activating factor (PAF). This possibility has been considered for several years, in view of the high incidence of thromboembolic disease in patients with hypereosinophilia, and the demonstration of PAF in supernatants from stimulated eosinophils was confirmed in later work (Lee et al. 1984) . However, why eosinophils should make this potent mediator is not clear, but it has been suggested that eosinophil-derived PAF, via its actions on smooth muscle and platelets, might also be involved in the pathogenesis of asthma (Basram et al. 1984) .
Eosinophil secretion
Although it has been known for many years that eosinophils have receptors for complexed IgG and complement, it has only recently become clear that they also have low affinity receptors for IgE, which are involved in secretion (Khalife et al. 1985) and can induce parasite killing. In addition to these relatively well defined membrane constitutents, lactoperoxidase labelling of the membrane proteins has brought to light a much wider range of constituents, most of which have as yet no known function. However, one of these, lysophospholipase, has been isolated, and shown to form Charcot-Leyden crystals (Weller et al. 1984 ). This has resolved the longstanding issue of the origin of these crystals, and their significance. However, it has not explained why eosinophils should possess large quantities of this enzyme, whose role is unknown, but is probably linked to its capacity to inactivate lysophospholipids which could damage tissues.
The recent development of monoclonal antibodies to eosinophil membrane antigens has provided approaches to the study of how eosinophil functions are regulated. Six antibodies have been developed which induce eosinophil secretion, or act synergistically with other inducers of eosinophil secretion Vadas 1984, Tai et al. 1985 and in preparation) . Although this work is at an early stage, it may lead to the isolation of the membrane constituents which regulate eosinophil activation, degranulation, and their toxic effects on parasites and tissues. At present, the studies have shown that there are additional structures in the membrane, besides receptors, for immunoglobulin and complement (Tai & Spry 1980) , which affect secretion.
These findings may explain the observation that some patients without raised serum IgE levels, in whom there was no obvious sign of complement activation or immune complex formation, had many degranulated eosinophils in the blood and tissue ). It was difficult to explain how these cells came to lose their granule contents, and attempts to find components in serum from these patients which induced degranulation, were unsuccessful.
Hypereosinophilic syndromes
Although many patients with a marked eosinophilia had been described previously (e.g. Stillman 1912), it was not until 1974 that the idiopathic hypereosinophilic syndrome was separated as a distinct entity (see Spry 1982) . Before then, patients with this syndrome had been thought to have eosinophilic leukaemia or eosinophilic leukaemoid reactions. The syndrome affects men more than women (9:1), and has a peak incidence at age 33. Some of these patients have had an allergic disease previously or recovered from a parasitic disease. Occasionally, patients with a parasitic disease may be difficult to diagnose by current clinical techniques, and a trial of antiparasitic treatment may resolve the eosinophilia. Long-term follow-up studies have shown that the idiopathic hypereosinophilic syndrome may have been initiated by one of a number of different processes, but in all cases the possible initiating disease has disappeared by the time the patients are investigated, and the eosinophilia usually persists for the rest of the patient's life. There is no cure available at present, although some patients appear to have a spontaneous 'remission', when the eosinophilia disappears for several months or years. Occasional patients have been reported with chromosomal abnormalities, but these are clearly not a prerequisite for the development of the disease (Parreira et al. 1985) . Most patients live for over 10 years or more without developing an acute or chronic leukaemia. How far growth regulatory substances (such as lymphocyte-derived growth factors) or intrinsic defects in eosinophil precursors may be involved in the excessive eosinopoiesis in these patients, remains to be determined.
However, many of these patients develop serious complications, including eosinophilic endomyocardial disease (Loffler's endomyocardial fibrosis) and thromboembolic disease. Two groups of patients have been studied in detail: one in the National Institutes of Health, Bethesda (Schooley et al. 1981 , Moore et al. 1985 , and one at Hammersmith Hospital, London, where clinical work has centered on defining the cardiovascular ) and thromboembolic complications . Laboratory studies initially demonstrated that all of the patients with eosinophilic heart disease had many blood eosinophils with less than the normal number of granules. This raised the possibility that blood eosinophils might have degranulated into the blood, releasing cardiotoxic constituents (Spry & Tai 1976) . Subsequent work has supported this possibility (Olsen & Spry 1985) . Activated and degranulating eosinophils have been shown to be present in acute necrotic lesions in the heart , Tai et al. 1984a , and our recent demonstration of secreted eosinophil granule proteins in these lesions has strengthened the hypothesis (Tai et al., in preparation) . In vitro studies with eosinophil granule proteins have shown how they might injure cardiac cells in vivo (Tai et al. 1982) . At the same time, the clinical and haematological complications of the hypereosinophilic syndrome were described in detail, and a considerable experience in steroid and other drug treatment regimens has developed. This has resulted in a markedly improved life expectancy and quality of life for patients with this unusual syndrome.
Conclusions
Many previous studies on eosinophils have failed to demonstrate significant differences between them and neutrophils. However, the demonstration of a unique profile of storagegranule constituents, and the remarkable capacity of these cells to release potent membranederived and storage-granule toxic constituents, has confirmed the view that they must play a significant role in allergic reactions where they are commonly found. Ten years ago, much of the emphasis on the role of eosinophils in disease centered on their presumed capacity to neutralize mediators of inflammatory responses. Today the emphasis has changed completely, and eosinophils are now seen by many working in this field to be primary mediators of inflammatory responses. The susceptibility of certain cells in tissues to the biological effects of eosinophil constituents may explain the clinical associations between eosinophils and certain disorders, such as eosinophilic heart disease, chronic fibrotic reactions associated with eosinophils, and thromboembolic diseases in patients with hypereosinophilia . Future work on eosinophils is likely to be affected significantly by the development of molecular biological approaches to the study of these cells, which may lead to a clearer understanding of the relationship between the different storage-granule proteins and their involvement in disease. Once the principal stimuli which induce eosinophil activation and degranulation have been identified, new approaches may become available for altering this in patients with an eosinophilia, either to enhance the capacity of eosinophils to eliminate parasites or, alternatively, to reduce the injurious effects of eosinophils on cells and tissues in patients with chronic eosinophilic disorders. It is also likely that many of these features will explain why eosinophils are a separate cell type in all mammalian species, and why evolutionary pressures have led to the development of eosinophilic responses in such a wide range of diseases.
